CN103031371A - CDH1 gene mutation detection specific primer and liquid chip - Google Patents
CDH1 gene mutation detection specific primer and liquid chip Download PDFInfo
- Publication number
- CN103031371A CN103031371A CN201110301967XA CN201110301967A CN103031371A CN 103031371 A CN103031371 A CN 103031371A CN 201110301967X A CN201110301967X A CN 201110301967XA CN 201110301967 A CN201110301967 A CN 201110301967A CN 103031371 A CN103031371 A CN 103031371A
- Authority
- CN
- China
- Prior art keywords
- seq
- site
- sequence
- comprised
- primer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The invention discloses a CDH1 gene mutation detection specific primer and a liquid chip. The liquid chip mainly comprises ASPE primers consisting of tag sequences at a 5' end and specific primer sequences aiming at target gene mutation sites at a 3' end, microspheres coated with anti-tag sequences and an amplification primer, wherein the specific primer sequences are as follows: SEQ ID NO.11 and SEQ ID NO.12 which aim at a D370H site, SEQ ID NO.13 and SEQ ID NO.14 which aim at an A6434V site, SEQ ID NO.15 and SEQ ID NO.16 which aim at an R732Q site, SEQ ID NO.17 and SEQ ID NO.18 which aim at a V82fs*13 site, and/or SEQ ID NO.19 and SEQ ID NO.20 which aim at a T263fs*3 site. The detection liquid chip provided by the invention has the advantages that the matching rate between the detection result and a sequencing method is up to 100%, and the wild-type and mutant parallel detection of multiple mutant sites can be realized.
Description
Technical field
The invention belongs to biology field, relate to medical science and biotechnology, concrete a kind of CDH1 detection in Gene Mutation Auele Specific Primer and the liquid-phase chip of relating to.
Background technology
E-cadherin encoding gene (E-Cadherin, CDH1) is a kind of tumor suppressor gene and anti-metastasis gene, and is closely related with generation, development, the Invasion and Metastasis of the malignant tumour of multiple epithelial origin.The CDH1 assignment of genes gene mapping is comprised of 1237 VITAMIN B4,1177 cytosine(Cyt)s, 1128 guanines and 1236 thymus pyrimidines in 16q22.1, there are some researches show that the CDH1 transgenation is relevant with the generation of tumour.
At present, the method that determination and analysis is carried out in the CDH1 transgenation seldom mainly contains direct sequencing and PCR-RFLP analytical method, and wherein the most frequently used method has the PCR-RFLP analytical method.The PCR-RFLP method is based on the change of the restriction enzyme enzyme recognition site that transgenation causes, as losing or produce novel site in the site, by a certain specific fragment of pcr amplification, use again the digestion with restriction enzyme amplified production, the size of electrophoresis observation fragment, this method can directly be judged genotype for detection of the transgenation that restriction enzyme site changes, but this method can not be used for not producing the detection in Gene Mutation of new restriction enzyme site.Again, more than these methods all exist the limitation that detects flux, can only detect a kind of mutation type at every turn, can not satisfy the needs of practical application.
Summary of the invention
One of purpose of the present invention provides the CDH1 gene mutation detection liquid-phase chip, and this liquid-phase chip can be used for separately or parallel detection CDH1 gene five kinds of common genotypic D370H, A634V, R732Q, V82fs*13 and T263fs*3 wild-type and mutants.
Realize that the above-mentioned purpose technical scheme is as follows:
A kind of CDH1 gene mutation detection liquid-phase chip includes:
(A). the wild-type that designs respectively for the different mutational sites of CDH1 gene and the ASPE primer of mutant: every kind of ASPE primer is comprised of the tag sequence of 5 ' end and 3 ' the end specific primer sequence for the goal gene mutational site, and described specific primer sequence is: for SEQ ID NO.11 and the SEQ ID NO.12 in D370H site; SEQ ID NO.13 and SEQ ID NO.14 for the A634V site; SEQ ID NO.15 and SEQ ID NO.16 for the R732Q site; SEQ ID NO.17 and SEQ ID NO.18 for the V82fs*13 site; And/or for SEQ ID NO.19 and the SEQ ID NO.20 in T263fs*3 site; Described tag sequence is selected from SEQ ID NO.1～SEQ ID NO.10;
(B). anti-tag sequence microballoon coated, that have the different colours coding is arranged, also be provided with the spacerarm sequence in the middle of described anti-tag sequence is connected with microballoon; Described anti-tag sequence is selected from SEQ ID NO.21～SEQ ID NO.30, and described anti-tag sequence can be correspondingly with (A) in selected tag sequence complementary pairing;
(C). be used for amplifying the primer that needs target sequence detection, that have corresponding mutational site.
Preferably, described amplimer is: for SEQ ID NO.31 and the SEQ ID NO.32 in D370H site; SEQ ID NO.33 and SEQ ID NO.34 for the A634V site; SEQ ID NO.35 and SEQ ID NO.36 for the R732Q site; SEQ ID NO.37 and SEQ ID NO.38 for the V82fs*13 site; And/or for SEQ ID NO.39 and the SEQ ID NO.40 in T263fs*3 site.
Preferably, described ASPE primer is: the sequence that is comprised of SEQ ID NO.1 and SEQ ID NO.11 for the D370H site reaches the sequence that is comprised of SEQ ID NO.2 and SEQ ID NO.12; The sequence that is comprised of SEQ ID NO.3 and SEQ IDNO.13 for the A634V site reaches the sequence that is comprised of SEQ ID NO.4 and SEQ ID NO.14; The sequence that is comprised of SEQ IDNO.5 and SEQ ID NO.15 for the R732Q site reaches the sequence that is comprised of SEQ ID NO.6 and SEQ ID NO.16; The sequence that is comprised of SEQ ID NO.7 and SEQ ID NO.17 for the V82fs*13 site reaches the sequence that is comprised of SEQ ID NO.8 and SEQ IDNO.18; And/or for the sequence that is formed by SEQ ID NO.9 and SEQ ID NO.19 in T263fs*3 site and the sequence that is formed by SEQ ID NO.10 and SEQ ID NO.20.
Another object of the present invention provides the Auele Specific Primer for the CDH1 detection in Gene Mutation.
Realize that the above-mentioned purpose technical scheme is as follows: described specific primer sequence is: for SEQ ID NO.11 and the SEQ ID NO.12 in D370H site; SEQ ID NO.13 and SEQ ID NO.14 for the A634V site; SEQ IDNO.15 and SEQ ID NO.16 for the R732Q site; SEQ ID NO.17 and SEQ ID NO.18 for the V82fs*13 site; And/or for SEQ ID NO.19 and the SEQ ID NO.20 in T263fs*3 site.
Major advantage of the present invention is:
1. the identical rate of the detected result of CDH1 gene mutation detection liquid-phase chip provided by the present invention and sequencing is up to 100%, and detects the needed time well below sequencing technologies commonly used, and realistic especially application needs.Prepared CDH1 gene mutation detection liquid-phase chip has extraordinary signal-noise ratio, and basically there is not cross reaction between designed probe and the anti-tag sequence, choosing and tag sequence label and the specifically combination of ASPE primer of tag sequence label, anti-tag sequence label, can avoid cross reaction, realize the parallel detection in a plurality of mutational sites.
2. the present invention has chosen optimum combination by the design experiences of contriver's long-term accumulation and a large amount of experimental implementation from numerous Auele Specific Primers.The ASPE primer specificity primer of the present invention's design can sensitive be identified the mutational site of target detect specifically, accurately distinguishes the genotype of various types; In same reaction system, between the different Auele Specific Primers, basically do not have cross reaction between the pcr amplification product of Auele Specific Primer and non-target detect, detection specificity is good, and cross reacting rate is lower than 3%; Except detecting Single locus sudden change situation, the also sudden change situation in a plurality of mutational sites of simultaneously parallel detection, it is consistent to detect effect.
3. detection method step of the present invention is simple, five kinds of mutational sites are detected and can be finished five amplifications that contain the target sequence in mutational site by a step PCR, many uncertain factors of existing in the complex operations processes such as repeated multiple times PCR have been avoided, thereby can greatly improve Detection accuracy, embodied accurate while qualitative and quantitative analysis feature.
4. not only to have overcome traditional solid phase chip susceptibility not high in the present invention, and the defective that the repeatability of detected result is poor is improved existing liquid-phase chip technology simultaneously, so that prepared microballoon can be applicable to different test items, has very strong expansion.The fluorescent signal value that detects improves greatly, thereby so that the sensitivity that detects is further enhanced, signal to noise ratio strengthens, and detected result more accurately and reliably.
Embodiment
Embodiment 1
The described CDH1 gene mutation detection liquid-phase chip of present embodiment mainly includes:
One, ASPE primer
Wild-type and mutant for CDH1 gene five kinds of common genotypic D370H, A634V, R732Q, V82fs*13 and T263fs*3 design respectively specific primer sequence.The ASPE primer is comprised of " tag sequence+specific primer sequence ".The ASPE primer sequence is as shown in the table:
The ASPE primer sequence (tag sequence+specific primer sequence) of table 1CDH1 gene
Every the ASPE primer comprises two parts, and 5 ' end is the specificity tag sequence for anti-tag sequence on the corresponding microballoon, and 3 ' end is mutant or the special primer fragment (as shown in Table 1 above) of wild-type.All ASPE primers are synthetic by Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.Every primer after synthetic is mixed with respectively the stock solution of 100pmol/mL with 10mmol/L Tris Buffer.
Two, the coated microballoon of anti-tag sequence
According to designed ASPE Auele Specific Primer fragment, select the tag sequence, reduce to greatest extent between the anti-tag sequence of each microballoon and secondary structure that tag and ASPE Auele Specific Primer fragment may form, corresponding anti-tag sequence is as shown in table 2 on 10 kinds of microballoons numberings of selection and the microballoon:
Corresponding anti-tag sequence on table 2 microballoon numbering and the microballoon
10 kinds of microballoons selecting are coated in the anti-tag sequence on the microballoon available from U.S. Luminex company.Be connected with the spacerarm sequence of 5-10 T between anti-tag sequence and the microballoon, namely add the spacerarm sequence of the preceding paragraph 5-10 T before each anti-tag sequence, the anti-tag sequence is synthetic by Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.With synthetic anti-tag sequence sterilization ddH
20 is made into the stock solution of 100nmol/ml.Described spacerarm is for being used for anti-tag and microsphere surface is spaced apart or anti-tag is placed the sequence of hydrophilic environments.By the spacerarm sequence of suitable length is set between anti-tag sequence and microballoon, can reduce sterically hinderedly, improve the efficient of hybridization and the specificity of hybridization.Common spacerarm sequence comprises poly dT, i.e. poly (dT), and oligomerization four polyoxyethylene glycol and (CH2) n spacerarm (n 〉=3) are such as (CH2) 12, (CH2) 18 etc.In addition, if exist poly (dA) to disturb, can also use poly (TTG) as spacerarm.Spacerarm of the present invention is preferably 5-10 T, and the process that microballoon is coated with is as follows:
Get respectively 5 * 10
6The carboxylated microballoon of individual above-mentioned numbering (available from Luminex company) is suspended in the MES solution of 50ul 0.1mol/L (pH4.5), adds the synthetic anti-tag molecule (100nmol/ml) of 10ul.EDC (N-(3-Dimethylaminopropyl-N-ethylcarbodiimide) (available from the Pierce Chemical company) working fluid of preparation 10ng/ml.The EDC working fluid that adds 2.5ul in the microballoon suspension, constant-temperature incubation 30 minutes adds the EDC working fluid of 2.5ul again, and constant-temperature incubation is 30 minutes again.After reaction finished, the Tween-20 washing with 0.02% was once washed once with 0.1% SDS liquid again.The microballoon that is coated with the anti-tag sequence after the washing is resuspended in the Tris-EDTA solution [10mmol/L Tris (pH8.0)] of 100ul, and among the 1mmol/L EDTA, 2-8 ℃ keeps in Dark Place.
Three, amplify the primer of the target sequence that contains the mutational site
For CDH1 gene five kinds of common genotypic D370H, A634V, R732Q, V82fs*13 and T263fs*3, design of amplification primers amplifies 5 target sequences that contain the mutational site to (seeing Table 3).
Table 3 amplifies the primer of the target sequence with mutational site
All primers are synthetic by Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.Every primer after synthetic is mixed with respectively the stock solution of 100pmol/mL with 10mmol/L Tris Buffer.
Embodiment 2 uses embodiment 1 described CDH1 gene mutation detection liquid-phase chip to the detection of sample
The prescription of described various solution is as follows:
MES damping fluid (pH5.0) prescription (250ml) of 50mM:
2 * Tm hybridization buffer
| Reagent | The source | Final concentration | The consumption of every 250ml |
| 1MTris-HCl，pH8.0 | SigmaT3038 | 0.2M | 50ml |
| 5MNaCl | Sigma S5150 | 0.4M | 20ml |
| Triton X-100 | Sigma T8787 | 0.16％ | 0.4ml |
Be stored in 4 ℃ after the filtration.
The ExoSAP-IT test kit is available from U.S. USB company.
Biotin labeled dCTP is available from Shanghai Sangon Biological Engineering Technology And Service Co., Ltd.
One, the DNA extraction of sample:
With reference to " molecular cloning " methods involving about DNA extraction, obtain DNA to be detected.
Two, the pcr amplification of testing sample
Design 5 pairs of primers, one step of multiplex PCR amplifies 5 target sequences that contain respectively CDH1 gene five kinds of common genotypic D370H, A634V, R732Q, V82fs*13 and T263fs*3, the product size is respectively 221bp, 215bp, 312bp, 205bp and 216bp, and primer sequence (SEQ IDNO.31-40) is seen shown in the above-mentioned table 3.
At first prepare the multiple PCR primer working fluid: respectively get respectively the primer stock solution 100ul of SEQ ID NO.31-40 in the 1.5ml Eppendorf tube, mix and be the multiple PCR primer working fluid.The multi-PRC reaction system is as follows:
The pcr amplification program is: 95 ℃ of 3min; 94 ℃ of 30s, 56 ℃ of 30s, 72 ℃ of 40s, 30 circulations; 72 ℃ of 10min; 4 ℃ save backup.
Three, the enzyme of PCR product is cut processing
1. get the reacted product of 7.5ul PCR, add 1ul 10 * SAP damping fluid, 1ul SAP enzyme and 0.5ul Exo-I enzyme;
2.37 ℃ hatch 15min, hatch 15min for 80 ℃, the enzyme that deactivation is unnecessary.The product that enzyme is cut after the processing is directly used in follow-up ASPE primer extension reaction.
Four, site-specific primer extension reaction (ASPE)
Utilize the ASPE primer of above-mentioned design to carry out primer extension reaction, in reaction process, mix biotin labeled dCTP, thereby make a plurality of biotin labeling on the reacted product band.
At first prepare the ASPE primer working fluid that mixes: get respectively the corresponding wild-type of gene to be detected and mutant ASPE primer stock solution 10ul in the 1.5ml Eppendorf tube, add 10mmol/L Tris Buffer and mend to 200ul, mix and be ASPE mix primer working fluid.The system of ASPE reaction is as follows:
Response procedures is: 96 ℃ of 2min; 94 ℃ of 30s, 54 ℃ of 1min, 72 ℃ of 2min, 30 circulations; 4 ℃ save backup.
Five, hybridization
According to the design the ASPE primer, the corresponding 10 kinds of coated microballoons of every group selection (as described in Example 1), every kind of microballoon concentration is 2.5 * 10
5Individual/ml;
2. get respectively the microballoon of every kind of numbering of 1ul in the Eppendorf tube of 1.5ml;
3. microballoon is in 〉=centrifugal the 1-2min of 10000g;
4. supernatant discarded, microballoon is resuspended in 2 * Tm hybridization buffer of 100ul, the vortex mixing;
5. get the above-mentioned microballoon suspension of 25ul in the corresponding hole of 96 hole filter plates, control wells adds the ddH of 25ul
2O;
6. get the ASPE reaction solution of 5-25ul in corresponding hole, use ddH
2O complements to 50ul;
7. encase 96 orifice plates with lucifuge with masking foil, 95 ℃ of 60s, 37 ℃ of 15min are hatched hybridization;
8. the microballoon after the hybridization is in 〉=centrifugal the 2-5min of 3000g;
9. remove supernatant, microballoon is resuspended in 1 * Tm hybridization buffer of 75ul;
10. microballoon is in 〉=centrifugal the 2-5min of 3000g;
11. microballoon is resuspended in 1 * Tm hybridization buffer of 75ul, adding 15ul concentration is the SA-PE (SA-PE) of 10ug/ml;
12.37 ℃ hatch 15min, on the Luminex instrument, detect.
Six, the result detects and data analysis
The reaction after product detects by Luminex serial analysis instrument.Greater than 100 as the cut-off value, the MFI value that detects when mutant is judged that there is this mutation type in this sample, otherwise is judged that this sample is corresponding wild-type greater than 100 the time take mutant fluorescent value (MFI).
Use present method to detect the CDH1 transgenation of great amount of samples, compare with the liquid-phase chip result with the sequencing detection, calculate the identical rate of method detected result provided by the present invention.Present method detects 20 increments CDH1 genotype detection result and the sequencing result rate of coincideing originally and reaches 100%.As seen CDH1 gene mutation detection liquid-phase chip provided by the present invention can detect the mutation type of CDH1 gene exactly, and the result is reliable and stable.
One of table 4 pattern detection result (MFI)
Table 5 sample CDH1 gene mutation type analytical results
| Catalogue number(Cat.No.) | The liquid-phase chip detected result | Sequencing result |
| 1 | The V82fs*13 sudden change | The V82fs*13 sudden change |
| 2 | Wild-type | Wild-type |
| 3 | Wild-type | Wild-type |
| 4 | Wild-type | Wild-type |
| 5 | The D370H sudden change | The D370H sudden change |
| 6 | Wild-type | Wild-type |
| 7 | Wild-type | Wild-type |
| 8 | The V82fs*13 sudden change | The V82fs*13 sudden change |
| 9 | Wild-type | Wild-type |
| 10 | Wild-type | Wild-type |
| 11 | The A634V sudden change | The A634V sudden change |
| 12 | The T263fs*3 sudden change | The T263fs*3 sudden change |
| 13 | Wild-type | Wild-type |
| 14 | Wild-type | Wild-type |
| 15 | Wild-type | Wild-type |
| 16 | Wild-type | Wild-type |
| 17 | The D370H sudden change | The D370H sudden change |
| 18 | Wild-type | Wild-type |
| 19 | Wild-type | Wild-type |
| 20 | Wild-type | Wild-type |
The liquid-phase chip of the ASPE primer that embodiment 3 is different is to the detection of CDH1 gene mutation site
One, the design (selection of tag sequence and Anti-tag sequence) of liquid-phase chip preparation
Detect liquid-phase chip as example take CDH1 gene D370H and R732Q site mutation, respectively for the wild-type of D370H and R732Q and the specific primer sequence of mutant design ASPE primer 3 ' end, the tag sequence of ASPE primer 5 ' end then is selected from SEQ ID NO.1-SEQ ID NO.10, accordingly, the anti-tag sequence with corresponding tag sequence complementary pairing that is coated on the microballoon is selected from SEQ ID NO.21-SEQ ID NO.30.Specific design is shown in following table (table 6).Synthetic, the coated microballoon of anti-tag sequence of ASPE primer, amplimer, detection method are described like embodiment 1 and embodiment 2.
The design of table 6 liquid-phase chip preparation
Two, sample detection
Adopt the liquid-phase chip of above-mentioned design preparation, by embodiment 2 described testing processes and method sample 21-40 is detected, detected result is as follows:
Table 7 pattern detection result and gene mutation analysis
Table 8 pattern detection result and gene mutation analysis
From experimental result as can be known, the ASPE primer uses different Tag sequences, and its result is still reliable and stable, but the ASPE primer is selected when the tag sequence is arranged in pairs or groups with specific primer sequence among the embodiment 1, effect better (signal to noise ratio is better) is referring to present embodiment test group 1 and test group 5.Other different tag sequences and specific primer sequence collocation, with coming to the same thing of embodiment 2 and present embodiment, concrete data are omitted.
Other is for the liquid-phase chip in different mutational sites, and the ASPE primer uses different Tag sequences, and its result is still reliable and stable, and selects when the tag sequence is with the specific primer sequence collocation among the embodiment 1, and effect is better, concrete data omission.
The selection of embodiment 4CDH1 detection in Gene Mutation specific primer sequence
One, the design (selection of wild-type and mutant specific primer sequence) of liquid-phase chip preparation
Detect liquid-phase chip as example take the mutational site of CDH1 Gene A 634V and R732Q, take the forward or backwards complementary sequence of this place, mutational site target sequence as template, respectively for the wild-type of A634V and R732Q and the specific primer sequence of mutant design ASPE primer 3 ' end, comprise preferred specific primer sequence and 2 alternative specific primer sequences in the embodiment of the invention 1, as shown in table 9.Wherein,
Interior base is the mutational site.
Table 9 specific primer sequence
Detect liquid-phase chip as example take the mutational site of CDH1 Gene A 634V and R732Q, select different specific primer sequences for A634V and R732Q, the tag sequence of ASPE primer 5 ' end then is fixed as the best effect sequence among the embodiment 1, and select with it corresponding anti-tag sequence, specific design is shown in following table (table 10).Synthetic, the coated microballoon of anti-tag sequence of ASPE primer, amplimer, detection method are described like embodiment 1 and embodiment 2.
Two of the design of table 10 liquid-phase chip preparation
Two, sample detection
Adopt the liquid-phase chip of above-mentioned design preparation, by embodiment 2 described testing processes and method sample 41-60 is detected, detected result is as follows:
Table 11 pattern detection result and gene mutation analysis
Table 12 pattern detection result and gene mutation analysis
By present embodiment as seen, when the ASPE primer was selected among the embodiment 1 collocation of specific primer sequence and tag sequence, effect better (signal to noise ratio is better) was referring to present embodiment test group 7 and test group 10.Other derives from different specific primer sequences and the collocation of tag sequence of the forward or backwards complementary sequence of place, target detect site sequence, with coming to the same thing of embodiment 2 and present embodiment, namely still be that the specific primer sequence described in the embodiment 1 is better from different tag sequence arranging effects, concrete data are omitted.
Other is for multiple specific primer sequence and the collocation of tag sequence in different mutational sites, with coming to the same thing of embodiment 2 and present embodiment, namely embodiment 1 selected Auele Specific Primer has better signal to noise ratio, it is also better to detect effect, and concrete data are omitted.
More than be for the specifying of possible embodiments of the present invention, but this embodiment limits claim of the present invention, allly do not break away from the equivalence that skill spirit of the present invention does and implement or change, all should be contained in the claim of the present invention.
Claims (6)
1. a CDH1 gene mutation detection liquid-phase chip is characterized in that, includes:
(A). the wild-type that designs respectively for the different mutational sites of CDH1 gene and the ASPE primer of mutant: every kind of ASPE primer is comprised of the tag sequence of 5 ' end and 3 ' the end specific primer sequence for the goal gene mutational site, and described specific primer sequence is: for SEQ ID NO.11 and the SEQ ID NO.12 in D370H site; SEQ ID NO.13 and SEQ ID NO.14 for the A634V site; SEQ ID NO.15 and SEQ ID NO.16 for the R732Q site; SEQ ID NO.17 and SEQ ID NO.18 for the V82fs*13 site; And/or for SEQ ID NO.19 and the SEQ ID NO.20 in T263fs*3 site; Described tag sequence is selected from SEQ ID NO.1～SEQ ID NO.10;
(B). anti-tag sequence microballoon coated, that have the different colours coding is arranged, also be provided with the spacerarm sequence in the middle of described anti-tag sequence is connected with microballoon; Described anti-tag sequence is selected from SEQ ID NO.21～SEQ ID NO.30, and described anti-tag sequence can be correspondingly with (A) in selected tag sequence complementary pairing;
(C). be used for amplifying the primer that needs target sequence detection, that have corresponding mutational site.
2. CDH1 gene mutation detection liquid-phase chip according to claim 1 is characterized in that, described amplimer is: for SEQ ID NO.31 and the SEQ ID NO.32 in D370H site; SEQ ID NO.33 and SEQ IDNO.34 for the A634V site; SEQ ID NO.35 and SEQ ID NO.36 for the R732Q site; SEQ ID NO.37 and SEQ ID NO.38 for the V82fs*13 site; And/or for SEQ ID NO.39 and the SEQ ID NO.40 in T263fs*3 site.
3. CDH1 gene mutation detection liquid-phase chip according to claim 1, it is characterized in that described ASPE primer is: the sequence that is comprised of SEQ ID NO.1 and SEQ ID NO.11 for the D370H site reaches the sequence that is comprised of SEQ ID NO.2 and SEQ ID NO.12; The sequence that is comprised of SEQ ID NO.3 and SEQ ID NO.13 for the A634V site reaches the sequence that is comprised of SEQ ID NO.4 and SEQ ID NO.14; The sequence that is comprised of SEQ ID NO.5 and SEQ ID NO.15 for the R732Q site reaches the sequence that is comprised of SEQ ID NO.6 and SEQ ID NO.16; The sequence that is comprised of SEQ ID NO.7 and SEQ IDNO.17 for the V82fs*13 site reaches the sequence that is comprised of SEQ ID NO.8 and SEQ ID NO.18; And/or for the sequence that is formed by SEQ ID NO.9 and SEQ ID NO.19 in T263fs*3 site and the sequence that is formed by SEQ ID NO.10 and SEQ ID NO.20.
4. CDH1 gene mutation detection liquid-phase chip according to claim 1 is characterized in that,
(A). described ASPE primer is: the sequence that is comprised of SEQ ID NO.1 and SEQ ID NO.11 for the D370H site reaches the sequence that is comprised of SEQ ID NO.2 and SEQ ID NO.12; The sequence that is comprised of SEQ ID NO.3 and SEQ IDNO.13 for the A634V site reaches the sequence that is comprised of SEQ ID NO.4 and SEQ ID NO.14; The sequence that is comprised of SEQID NO.5 and SEQ ID NO.15 for the R732Q site reaches the sequence that is comprised of SEQ ID NO.6 and SEQ ID NO.16; The sequence that is comprised of SEQ ID NO.7 and SEQ ID NO.17 for the V82fs*13 site reaches the sequence that is comprised of SEQ ID NO.8 and SEQ IDNO.18; Reach the sequence that is formed by SEQ ID NO.10 and SEQ ID NO.20 with the sequence that is formed by SEQ ID NO.9 and SEQ ID NO.19 for the T263fs*3 site;
(B). anti-tag sequence microballoon coated, that have the different colours coding is arranged, also be provided with the spacerarm sequence in the middle of described anti-tag sequence is connected with microballoon; Described anti-tag sequence is selected from SEQ ID NO.21～SEQ ID NO.30, and described anti-tag sequence can be correspondingly with (A) in selected tag sequence complementary pairing;
(C). described amplimer is: for SEQ ID NO.31 and the SEQ ID NO.32 in D370H site; SEQ ID NO.33 and SEQ ID NO.34 for the A634V site; SEQ ID NO.35 and SEQ ID NO.36 for the R732Q site; SEQ ID NO.37 and SEQ ID NO.38 for the V82fs*13 site; With SEQ ID NO.39 and the SEQID NO.40 for the T263fs*3 site.
5. each described CDH1 gene mutation detection liquid-phase chip is characterized in that according to claim 1-4, and described spacerarm is 5-10 T.
6. be used for the Auele Specific Primer of CDH1 detection in Gene Mutation, it is characterized in that, for SEQ ID NO.11 and the SEQID NO.12 in D370H site; SEQ ID NO.13 and SEQ ID NO.14 for the A634V site; SEQ IDNO.15 and SEQ ID NO.16 for the R732Q site; SEQ ID NO.17 and SEQ ID NO.18 for the V82fs*13 site; And/or for SEQ ID NO.19 and the SEQ ID NO.20 in T263fs*3 site.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110301967.XA CN103031371B (en) | 2011-09-30 | 2011-09-30 | CDH1 gene mutation detection specific primer and liquid chip |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110301967.XA CN103031371B (en) | 2011-09-30 | 2011-09-30 | CDH1 gene mutation detection specific primer and liquid chip |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103031371A true CN103031371A (en) | 2013-04-10 |
| CN103031371B CN103031371B (en) | 2014-11-26 |
Family
ID=48018770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110301967.XA Active CN103031371B (en) | 2011-09-30 | 2011-09-30 | CDH1 gene mutation detection specific primer and liquid chip |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103031371B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101984070A (en) * | 2010-09-21 | 2011-03-09 | 广州益善生物技术有限公司 | c-KIT gene mutation detection liquid-phase chip |
-
2011
- 2011-09-30 CN CN201110301967.XA patent/CN103031371B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101984070A (en) * | 2010-09-21 | 2011-03-09 | 广州益善生物技术有限公司 | c-KIT gene mutation detection liquid-phase chip |
Non-Patent Citations (2)
| Title |
|---|
| GIANPAOLO ET AL: "A model to infer the pathogenic significance of CDH1 germline missense variants", 《J MOL MED》, 16 August 2006 (2006-08-16), pages 1, XP019451571, DOI: doi:10.1007/s00109-006-0091-z * |
| 周春宇等: "遗传性弥漫型胃癌与CDH1 基因", 《中国普外基础与临床杂志》, vol. 16, no. 11, 31 December 2009 (2009-12-31), pages 944 - 947 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103031371B (en) | 2014-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102994619A (en) | NRAS gene mutation detection specificity primer and liquid chip thereof | |
| CN102994621B (en) | PTPN11 gene mutation detection specificity primer and liquid chip thereof | |
| CN102994617A (en) | HRAS gene mutation detection specificity primer and liquid chip thereof | |
| CN103374609B (en) | ABO gene mutation detection specific primers and liquid chip | |
| CN103031370B (en) | RB1 gene mutation detection specific primer and liquid chip | |
| CN103031369B (en) | CDKN2A gene mutation detection specific primer and liquid chip | |
| CN103031365B (en) | ATM gene mutation detection specific primer and liquid chip | |
| CN102912002B (en) | ABCB2 gene polymorphism detection specific primers and liquid chip | |
| CN103031371B (en) | CDH1 gene mutation detection specific primer and liquid chip | |
| CN103031367A (en) | VHL (Von Hippel Lindau) genetic mutation detection specific primer and liquid phase chip | |
| CN102994620B (en) | AKT1 gene mutation detection specificity primer and liquid chip thereof | |
| CN102304567B (en) | Polymorphic detection specific primers and liquid phase chip in 8 q 24 section of chromosome | |
| CN102191336B (en) | MYC gene single nucleotide polymorphism (SNP) detection specific primer and liquid-phase chip | |
| CN103031368B (en) | FGFR1 gene mutation detection specific primer and liquid chip | |
| CN102181573B (en) | Specific primers and liquid-phase chip for detection of KITLG gene | |
| CN102994625B (en) | PIK3R1 gene mutation detection specificity primer and liquid chip thereof | |
| CN102994623B (en) | STK11 gene mutation detection specificity primer and liquid chip thereof | |
| CN103031366B (en) | FGFR2 gene mutation detection specific primer and liquid chip | |
| CN102994616B (en) | MEK1 gene mutation detection specificity primer and liquid chip thereof | |
| CN102888444B (en) | Factor II and Factor V genetic polymorphism detection specific primer and liquid-phase chip | |
| CN102952868B (en) | Specific primer and liquid chip for detecting polymorphism of SLC15A2 gene | |
| CN102912005A (en) | CYP2C8 gene polymorphism detection specific primers and liquid chip | |
| CN102952870B (en) | Specific primer and liquid chip for detecting polymorphism of SLC22A2 gene | |
| CN102191335B (en) | Specific primer and liquid-phase chip for SNP (single nucleotide polymorphism) detection of PIGU (phosphatidylinositol glycan anchor biosynthesis, class U) genes | |
| CN102304564B (en) | Specific primers and liquid phase chip for single nucleotide polymorphism (SNP) detection in 15 q 25 section of chromosome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C53 | Correction of patent of invention or patent application | ||
| CB02 | Change of applicant information |
Address after: Five 510663 Guangdong city of Guangzhou province Guangzhou Science City Moon Road No. 80, Guangzhou technology innovation base B, C Applicant after: Surexam Biological Technology Co., Ltd. Address before: Five 510663 Guangdong city of Guangzhou province Guangzhou Science City Moon Road No. 80, Guangzhou technology innovation base B, C Applicant before: Guangzhou Yishan Biotechnology Co., Ltd. |
|
| COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: GUANGZHOU YISHAN BIOTECHNOLOGY CO., LTD. TO: SUREXAM BIOTECHNOLOGY CO., LTD. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |